ATNF) issues letter to shareholders from CEO Dr. James Woody

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on developing new drugs that address unmet needs in inflammatory diseases, fibrosis and pain, today issued a letter to shareholders of its managing director James Woody, MD, Ph.D. In the letter, Dr. Woody commented on the company’s current share price, indicating that 180 Life Sciences is not an anomaly as the market and the biotechnology sector have experienced a precipitous decline and approached a confluence. contributing factors. “While we cannot influence these factors, we continue to advance our mission to bring patients the therapies they so desperately need. Additionally, as previously disclosed in our SEC filings, certain executives and members of the Company’s Board of Directors have purchased stock on the open market at a price per share above our current price and those executives remain excited. by the future potential of society,” Dr. Woody said in the update. “While we are not happy with the recent decline, we have unwavering confidence in the business and remain focused on building fundamental value which we believe will ultimately be reflected over time.”

To view the full press release, visit https://ibn.fm/9swCT

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on developing new medicines that address unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of leading therapeutics at the University from Oxford, Hebrew University and Stanford University. 180 Life Sciences leads research aimed at solving one of the world’s greatest vectors of disease: inflammation. The company conducts groundbreaking studies in clinical programs, which seek to develop new drugs that address distinct areas of inflammation for which there are no effective therapies. The company’s main platform is a new fibrosis treatment program using anti-TNF (tumor necrosis factor). For more information, visit the company’s website at www.180LifeSciences.com.

NOTICE TO INVESTORS: The latest news and updates relating to the ATNF can be found in the company’s newsroom at http://ibn.fm/ATNF

About InvestorWire

InvestorWire is the transfer service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wired broadcast products you’ll need to ensure your next press release grabs your target audience’s attention and stays with you. While our competitors turn to you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all national versions. While other delivery services can provide a basic review of your release, InvestorWire helps you put your best foot forward with Improved press release.

With our competitors, the job is done the second your version crosses the line. Not with InvestorWire. We include follow-up coverage of each release taking advantage of the ever-growing audiences of the 50+ brands who make up the InvestorBrandNetwork.

Get the most out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please review the full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or republished: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, California 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Comments are closed.